Skip to Main Content

Author Details

Catherine M Kelly
Mater Misericordiae University Hospital
2006
67
25
PMIDPaper TitleJournal TitlePublished Year
35141870Using menopausal hormone therapy after a cancer diagnosis in Ireland.Ir J Med Sci2023
37199377Impact of COVID-19 on health care and quality of life in women with breast cancer.JNCI Cancer Spectr2023
36743520Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.Ther Adv Med Oncol2023
36869943Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence.Support Care Cancer2023
36132153Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.Front Oncol2022
35999966Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.Cancer Manag Res2022
33438436A Multicenter Retrospective Review of Systemic Anti-Cancer Treatment and Palliative Care Provided to Solid Tumor Oncology Patients in the 12 Weeks Preceding Death in Ireland.Am J Hosp Palliat Care2021
33767972Overview of recent advances in metastatic triple negative breast cancer.World J Clin Oncol2021
33793299Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.J Clin Oncol2021
33622415Competing mortality risks: predicted cardiovascular disease risk versus predicted risk of breast cancer mortality in patients receiving adjuvant chemotherapy in a single Irish center.Cardiooncology2021
33835293Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.Breast Cancer Res Treat2021
33799597Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".Cancers (Basel)2021
3491433921-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.N Engl J Med2021
34869938The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer - Trial protocol of a phase II study.Contemp Clin Trials Commun2021
34754239Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience.Cancer Manag Res2021
34013530Oligometastatic breast cancer: Are we there yet?Int J Cancer2021
34125341Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.Breast Cancer Res Treat2021
34090143Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.Eur J Cancer2021
34312396Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.NPJ Breast Cancer2021
33449331Virtual oncology clinics during the COVID-19 pandemic.Ir J Med Sci2021
33478241Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.Circ Heart Fail2021
32708702Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland.Cancers (Basel)2020
33008323The psychosocial determinants of quality of life in breast cancer survivors: a scoping review.BMC Cancer2020
29766409Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer.Ir J Med Sci2019
29092024Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Ann Oncol2018
29373071Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.J Clin Oncol2018
27170025High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.Ann Clin Biochem2017
32913965Postmortem Examination of an Aggressive Case of Medullary Thyroid Carcinoma Characterized by Catastrophic Genomic Abnormalities.JCO Precis Oncol2017
28750640Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Breast Cancer Res2017
28611537Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.Breast Care (Basel)2017
26833487Get the GIST? An overview of gastrointestinal stromal tumours.Ir J Med Sci2016
26631838Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.Clin Breast Cancer2016
27830172An unusual case of basal cell carcinoma of the vulva with lung metastases.Gynecol Oncol Rep2016
27384237Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Oncologist2016
25240398Conformational dynamics and aggregation behavior of piezoelectric diphenylalanine peptides in an external electric field.Biophys Chem2015
26490026Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.Acta Med Okayama2015
26364296Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.Breast Cancer Res Treat2015
25729787Structure and dynamics of the fibronectin-III domains of Aplysia californica cell adhesion molecules.Phys Chem Chem Phys2015
25744290Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.Support Care Cancer2015
24767882First international consensus guidelines for breast cancer in young women (BCY1).Breast2014
25531722Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.Oncol Res Treat2014
25226719Vismodegib in the treatment of advanced BCC.Ir Med J2014
25033383Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.Expert Opin Drug Saf2014
23547718Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.BMC Cancer2013
24060333Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.Breast Cancer Res2013
24143122Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.Cancer Manag Res2013
23605692Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.Drugs2013
23633449Breast cancer genomics: challenges in interpretation and application.Oncologist2013
22331946Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.J Clin Oncol2012
23094782Vemurafenib for the treatment of melanoma.Expert Opin Pharmacother2012
  • 1 - 50 of 67

Recommended Authors

University of Milano
Career Start Year 2017
Number of shared co-authors 0
University of Milano
Career Start Year 2008
Number of shared co-authors 4
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 6
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 8
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 8
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 5
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 6
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 12
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 8
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 15
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 3
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 7
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 11
University of Milan
Career Start Year 1996
Number of shared co-authors 19
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 10
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 4
Dartmouth Cancer Center
Career Start Year 1993
Number of shared co-authors 6
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 9
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 4
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 0
Erasmus Medical Center
Career Start Year 1990
Number of shared co-authors 12
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 18
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 2
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 22
Memorial Sloan Kettering Cancer Center
Career Start Year 1976
Number of shared co-authors 10
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 8
Mayo Clinic
Career Start Year 1952
Number of shared co-authors 7

Collaborators

UCL Great Ormond Street Institute of Child Health, University College London
Co-authored papers 7
Co-authored papers 7
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Co-authored papers 5
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital
Co-authored papers 4
New York Presbyterian Hospital
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
University of Bern
Co-authored papers 3
Champalimaud Clinical Center/Champalimaud Foundation
Co-authored papers 3
Gloucestershire Hospitals NHS Foundation Trust
Co-authored papers 2
Co-authored papers 2
Ontario Institute for Cancer Research
Co-authored papers 2
University of Edinburgh
Co-authored papers 2
Co-authored papers 2
Clinical Investigations Branch, National Cancer Institute
Co-authored papers 2
American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University
Co-authored papers 2
Institut Jules Bordet
Co-authored papers 2
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 2
Lund University and Skane University Hospital
Co-authored papers 2
Fred Hutchinson Cancer Research Center
Co-authored papers 2
Sahlgrenska University Hospital
Co-authored papers 2
Co-authored papers 2
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 2
Co-authored papers 2
UCD Conway Institute, University College Dublin
Co-authored papers 2
Hospital of Vastmanland Vasteras
Co-authored papers 2
Leiden University Medical Center
Co-authored papers 2
UCD Conway Institute, University College Dublin
Co-authored papers 2
Mayo Clinic
Co-authored papers 2